Floatz logo

Dual-Target Car-Nk Cell Product

Fallopian Tube Carcinoma

Beijing BiotechCell therapyPhase 1/2Active
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
89/ 100

Competitive context

13 Active assets in the Fallopian Tube Carcinoma cohort.

Asset / SponsorPhaseRating
Carboplatin
University of Washington
Phase 3BB
Cyclophosphamide
Beijing Biotech
Phase 2BB
CIS-DIAMMINEDICHLOROPLATINUM II
The Netherlands Cancer Institute
Phase 3BB
Inno-206
Advenchen Laboratories, LLC
Phase 3BB
Olaparib
National Cancer Institute (NCI)
Phase 2B

View all 50 →

Same molecule, other indications

Dual-Target Car-Nk Cell Product is also rated in:

Recurrent or Refractory Disease After Standard TherapiesDormant
CCC
Indicative ·
48 / 100
View asset →
primary peritoneal carcinomaDormant
CC
Indicative ·
45 / 100
View asset →
ovarian carcinomaDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →